Suppliers / Yancheng Suhai Pharmaceutical

Yancheng Suhai Pharmaceutical

China 4 employees Updated 9 July 2026

Yancheng Suhai Pharmaceutical is an API manufacturer based in China. It holds one active US drug master file and 2 valid CEPs. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 17 April 2025 as NAI.

1
active US DMFs
2
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 17 April 2025 NAI US FDA
  • 26 April 2019 VAI US FDA
  • 13 March 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Dafeng District, Yancheng City, China Not on file
China, China 3002394098

What they file, and where

Molecule Regulators Docs
Doxycycline EDQM, US FDA 3

Also appears on these molecule pages

Doxycycline API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Yancheng Suhai Pharmaceutical

Does Yancheng Suhai Pharmaceutical hold a US DMF or a CEP?
Yancheng Suhai Pharmaceutical holds 1 active US drug master file and 2 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Yancheng Suhai Pharmaceutical FDA-registered?
One site operated by Yancheng Suhai Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Yancheng Suhai Pharmaceutical's last inspection go?
The most recent inspection on record closed on 17 April 2025 as NAI (No Action Indicated: nothing objectionable was found). 3 inspections are on file.
Where does Yancheng Suhai Pharmaceutical manufacture?
2 registered sites are on record, in China (Dafeng District, Yancheng City and China). Every site is listed on this page with the register it came from.
What does Yancheng Suhai Pharmaceutical make?
1 molecule is on record against Yancheng Suhai Pharmaceutical, including Doxycycline. Each links through to that molecule's full manufacturer list.
Which regulators recognise Yancheng Suhai Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Yancheng Suhai Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 17 April 2025.

Comparable suppliers

Changzhou Pharmaceutical Factory shares 1 molecule Maithri Drugs shares 1 molecule Gland Pharma shares 1 molecule Raks Pharma shares 1 molecule Hovione Farmaciência shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates